Identification of repurposed small molecule drugs for chordoma therapy

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS

(2011) R. Houot et al.   ANNALS OF ONCOLOGY

Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies

(2011) G. S. Falchook et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics

(2011) R. Huang et al.   Science Translational Medicine

Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action

(2010) Susanne C. Miller et al.   BIOCHEMICAL PHARMACOLOGY

The Next Step: Innovative Molecular Targeted Therapies for Treatment of Intracranial Chordoma Patients

(2010) Jeffrey J. Barry et al.   NEUROSURGERY

Bortezomib and Waldenstrom's macroglobulinemia

(2009) Laurent Pascal et al.   EXPERT OPINION ON PHARMACOTHERAPY

Proton therapy in chordoma of the base of the skull: a systematic review

(2009) Maurizio Amichetti et al.   NEUROSURGICAL REVIEW

Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α

(2009) A Soeda et al.   ONCOGENE

Characterization of Diversity in Toxicity Mechanism Using in Vitro Cytotoxicity Assays in Quantitative High Throughput Screening

(2008) Ruili Huang et al.   CHEMICAL RESEARCH IN TOXICOLOGY

From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage

(2008) S. Giordano et al.   CURRENT MEDICINAL CHEMISTRY

Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma

(2008) Stephanie L Wethington et al.   Expert Review of Anticancer Therapy

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway

(2008) S Wang   ONCOGENE